Aquinox Pharmaceuticals Inc. (AQXP) Upgraded by Zacks Investment Research to Hold
According to Zacks, “Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
A number of other analysts have also weighed in on the stock. Canaccord Genuity reaffirmed a buy rating and issued a $22.00 price target on shares of Aquinox Pharmaceuticals in a research note on Wednesday, August 17th. Leerink Swann started coverage on shares of Aquinox Pharmaceuticals in a research note on Tuesday. They issued an outperform rating and a $24.00 price target for the company. Finally, Jefferies Group upped their price target on shares of Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a hold rating in a research note on Friday, August 5th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Aquinox Pharmaceuticals currently has a consensus rating of Buy and an average price target of $20.29.
Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 0.98% during mid-day trading on Tuesday, reaching $14.08. 91,449 shares of the company’s stock traded hands. The company has a 50-day moving average of $12.06 and a 200-day moving average of $9.07. The company’s market capitalization is $242.34 million. Aquinox Pharmaceuticals has a 52-week low of $6.01 and a 52-week high of $16.75.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its earnings results on Thursday, August 4th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.22. Equities research analysts expect that Aquinox Pharmaceuticals will post ($2.23) EPS for the current year.
In other Aquinox Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker bought 2,783,605 shares of the business’s stock in a transaction that occurred on Tuesday, September 20th. The stock was acquired at an average cost of $12.25 per share, with a total value of $34,099,161.25. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.00% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in AQXP. Boxer Capital LLC raised its stake in Aquinox Pharmaceuticals by 7.0% in the second quarter. Boxer Capital LLC now owns 877,753 shares of the company’s stock valued at $5,811,000 after buying an additional 57,738 shares in the last quarter. Bridgeway Capital Management Inc. raised its stake in Aquinox Pharmaceuticals by 416.7% in the second quarter. Bridgeway Capital Management Inc. now owns 62,000 shares of the company’s stock valued at $410,000 after buying an additional 50,000 shares in the last quarter. Opaleye Management Inc. acquired a new stake in Aquinox Pharmaceuticals during the second quarter valued at approximately $1,953,000. BlackRock Fund Advisors raised its stake in Aquinox Pharmaceuticals by 1.8% in the second quarter. BlackRock Fund Advisors now owns 228,693 shares of the company’s stock valued at $1,514,000 after buying an additional 3,977 shares in the last quarter. Finally, BlackRock Advisors LLC raised its stake in Aquinox Pharmaceuticals by 2.1% in the second quarter. BlackRock Advisors LLC now owns 404,575 shares of the company’s stock valued at $2,678,000 after buying an additional 8,280 shares in the last quarter. 68.20% of the stock is owned by institutional investors and hedge funds.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.